Correlating quantitative susceptibility mapping with cognitive decline in Alzheimer's disease

Brain

Volumn 140, Issue 8, 2017, Pages 2069-2072

  Derry, Paul J ^a,b   Kent, Thomas A ^a,b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN;

ALZHEIMER DISEASE; COGNITIVE DEFECT; HUMAN; NEUROPSYCHOLOGICAL TEST;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; COGNITIVE DYSFUNCTION; HUMANS; NEUROPSYCHOLOGICAL TESTS;

EID: 85028319061     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awx167     Document Type: Note

References (9)

1. Atamna H, Boyle K. Amyloid-beta peptide binds with heme to form a peroxidase: relationship to the cytopathologies of Alzheimer's disease. Proc Natl Acad Sci USA 2006; 103: 3381-6.
2. Ayton S, Faux NG, Bush AI, Weiner MW, Aisen P, Petersen R, et al. Ferritin levels in the cerebrospinal fluid predict Alzheimer's disease outcomes and are regulated by APOE. Nat Commun 2015; 6: 6760.
3. Ayton S, Fazlollahi A, Bourgeat P, Raniga P, Ng A, Yen Ying L, et al. Cerebral quantitative susceptibility mapping predicts amyloidb-related cognitive decline. Brain 2017; 140: 2112-9.
4. Conrad M, Angeli JPF, Vandenabeele P, Stockwell BR. Regulated necrosis: disease relevance and therapeutic opportunities. Nat Rev Drug Discov 2016; 15: 348-66.
5. Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell 2012; 149: 1060-72.
6. Everett J, Céspedes E, Shelford LR, Exley C, Collingwood JF, Dobson J, et al. Evidence of redox-active iron formation following aggregation of ferri hydrate and the Alzheimer's disease peptide b-amyloid. Inorg Chem 2014; 53: 2803-9.
7. Huang Y, Mucke L. Alzheimer mechanisms and therapeutic strategies. Cell 2012; 148: 1204-22.
8. McLachlan DRC, Kruck TPA, Kalow W, Andrews DF, Dalton AJ, Bell MY, et al. Intramuscular desferrioxamine in patients with Alzheimer's disease. Lancet 1991; 337: 1304-8.
9. Sayre LM, Perry G, Harris PLR, Liu Y, Schubert KA, Smith MA. In situ oxidative catalysis by neurofibrillary tangles and senile plaques in Alzheimer's disease. J. Neurochem. 2001; 74: 270-279.